The Day In Review: Cell Genesys, Inc. Climbs On GVAX Results

Published: Apr 04, 2007

April 3, 2007 -- Cell Genesys reported GVAX produced an 84% increase in median survival of prostate cancer patients in a Phase II test; Theravance said two once-daily asthma drugs in Phase IIb trials were equal to twice-daily salmeterol; Repros Therapeutics announced uterine fibroid drug Proellex passed its Phase II test; Opexa said its T-cell vaccine Tovaxin was safe and effective in a Phase I/II trial in patients with multiple sclerosis; Ligand will pay a $2.50 dividend after selling off its appproved drugs; and Elan and Transition Therapeutics received Fast Track designation for their Alzheimer’s drug. The Centient Biotech 200™ rose 41 points to 3928, a gain of 1.06%. More details...

Back to news